Eduardo Castañón, MD, Universidad de Navarra, Pamplona, Spain, presents findings from a Phase I trial (NCT03946800) of MEDI1191, a lipid nanoparticle-formulated mRNA encoding IL-12 injected intratumorally, with durvalumab. The investigational combination was well tolerated in a majority of patients, and the overall response rate (ORR) was lower than expected, possible due to a small cohort. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть